IRADIMED CORP (IRMD) Stock Fundamental Analysis
USA - NASDAQ:IRMD - US46266A1097 - Common Stock
80.9 USD
+4.09 (+5.32%)
IRMD gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 189 industry peers in the Health Care Equipment & Supplies industry. Both the health and profitability get an excellent rating, making IRMD a very profitable company, without any liquidiy or solvency issues. IRMD is not valued too expensively and it also shows a decent growth rate. These ratings would make IRMD suitable for quality investing!
1. Profitability
1.1 Basic Checks
IRMD had positive earnings in the past year.
IRMD had a positive operating cash flow in the past year.
IRMD had positive earnings in each of the past 5 years.
IRMD had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
IRMD has a Return On Assets of 19.41%. This is amongst the best in the industry. IRMD outperforms 97.88% of its industry peers.
IRMD has a Return On Equity of 21.91%. This is amongst the best in the industry. IRMD outperforms 93.65% of its industry peers.
IRMD has a better Return On Invested Capital (19.30%) than 97.35% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for IRMD is significantly above the industry average of 9.02%.
The 3 year average ROIC (18.78%) for IRMD is below the current ROIC(19.30%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 19.41% | ||
| ROE | 21.91% | ||
| ROIC | 19.3% |
ROA(3y)17.74%
ROA(5y)13.28%
ROE(3y)21.21%
ROE(5y)15.76%
ROIC(3y)18.78%
ROIC(5y)N/A
1.3 Margins
The Profit Margin of IRMD (26.61%) is better than 94.71% of its industry peers.
IRMD's Profit Margin has been stable in the last couple of years.
With an excellent Operating Margin value of 30.67%, IRMD belongs to the best of the industry, outperforming 97.35% of the companies in the same industry.
IRMD's Operating Margin has improved in the last couple of years.
IRMD's Gross Margin of 76.96% is amongst the best of the industry. IRMD outperforms 88.89% of its industry peers.
In the last couple of years the Gross Margin of IRMD has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 30.67% | ||
| PM (TTM) | 26.61% | ||
| GM | 76.96% |
OM growth 3Y8.49%
OM growth 5Y5.96%
PM growth 3Y5.58%
PM growth 5Y0.99%
GM growth 3Y0.12%
GM growth 5Y-0.04%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so IRMD is creating value.
The number of shares outstanding for IRMD has been increased compared to 1 year ago.
The number of shares outstanding for IRMD has been increased compared to 5 years ago.
There is no outstanding debt for IRMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
IRMD has an Altman-Z score of 51.33. This indicates that IRMD is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of IRMD (51.33) is better than 98.94% of its industry peers.
There is no outstanding debt for IRMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 51.33 |
ROIC/WACC2.21
WACC8.75%
2.3 Liquidity
A Current Ratio of 8.78 indicates that IRMD has no problem at all paying its short term obligations.
With an excellent Current ratio value of 8.78, IRMD belongs to the best of the industry, outperforming 91.01% of the companies in the same industry.
IRMD has a Quick Ratio of 7.51. This indicates that IRMD is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 7.51, IRMD belongs to the top of the industry, outperforming 90.48% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.78 | ||
| Quick Ratio | 7.51 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 11.25% over the past year.
Measured over the past years, IRMD shows a quite strong growth in Earnings Per Share. The EPS has been growing by 13.92% on average per year.
Looking at the last year, IRMD shows a quite strong growth in Revenue. The Revenue has grown by 11.74% in the last year.
Measured over the past years, IRMD shows a quite strong growth in Revenue. The Revenue has been growing by 13.71% on average per year.
EPS 1Y (TTM)11.25%
EPS 3Y25.74%
EPS 5Y13.92%
EPS Q2Q%16.67%
Revenue 1Y (TTM)11.74%
Revenue growth 3Y20.55%
Revenue growth 5Y13.71%
Sales Q2Q%13.84%
3.2 Future
IRMD is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.21% yearly.
Based on estimates for the next years, IRMD will show a quite strong growth in Revenue. The Revenue will grow by 11.02% on average per year.
EPS Next Y13.75%
EPS Next 2Y14.21%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year10.65%
Revenue Next 2Y11.02%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 45.45 indicates a quite expensive valuation of IRMD.
Compared to the rest of the industry, the Price/Earnings ratio of IRMD indicates a somewhat cheap valuation: IRMD is cheaper than 68.78% of the companies listed in the same industry.
The average S&P500 Price/Earnings ratio is at 26.11. IRMD is valued rather expensively when compared to this.
The Price/Forward Earnings ratio is 37.59, which means the current valuation is very expensive for IRMD.
Compared to the rest of the industry, the Price/Forward Earnings ratio of IRMD indicates a somewhat cheap valuation: IRMD is cheaper than 71.43% of the companies listed in the same industry.
IRMD's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 22.55.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 45.45 | ||
| Fwd PE | 37.59 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, IRMD is valued a bit cheaper than the industry average as 68.78% of the companies are valued more expensively.
71.96% of the companies in the same industry are more expensive than IRMD, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 77.19 | ||
| EV/EBITDA | 37.56 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
IRMD has an outstanding profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as IRMD's earnings are expected to grow with 14.21% in the coming years.
PEG (NY)3.31
PEG (5Y)3.27
EPS Next 2Y14.21%
EPS Next 3YN/A
5. Dividend
5.1 Amount
IRMD has a yearly dividend return of 0.86%, which is pretty low.
IRMD's Dividend Yield is rather good when compared to the industry average which is at 1.89. IRMD pays more dividend than 91.53% of the companies in the same industry.
With a Dividend Yield of 0.86, IRMD pays less dividend than the S&P500 average, which is at 2.37.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.86% |
5.2 History
IRMD has been paying a dividend for less than 5 years, so it still needs to build a track record.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
39.33% of the earnings are spent on dividend by IRMD. This is a low number and sustainable payout ratio.
DP39.33%
EPS Next 2Y14.21%
EPS Next 3YN/A
NASDAQ:IRMD (11/3/2025, 12:27:53 PM)
80.9
+4.09 (+5.32%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners59.43%
Inst Owner Change-2.19%
Ins Owners36.81%
Ins Owner Change1.03%
Market Cap1.03B
Revenue(TTM)77.64M
Net Income(TTM)20.66M
Analysts82.5
Price Target76.5 (-5.44%)
Short Float %1.99%
Short Ratio3.17
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.86% |
Yearly Dividend1.08
Dividend Growth(5Y)N/A
DP39.33%
Div Incr Years0
Div Non Decr Years0
Ex-Date
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.43%
Min EPS beat(2)0.43%
Max EPS beat(2)10.44%
EPS beat(4)3
Avg EPS beat(4)4.6%
Min EPS beat(4)-1.96%
Max EPS beat(4)10.44%
EPS beat(8)6
Avg EPS beat(8)6.12%
EPS beat(12)10
Avg EPS beat(12)7.27%
EPS beat(16)14
Avg EPS beat(16)11.73%
Revenue beat(2)1
Avg Revenue beat(2)-0.52%
Min Revenue beat(2)-1.05%
Max Revenue beat(2)0.01%
Revenue beat(4)1
Avg Revenue beat(4)-0.62%
Min Revenue beat(4)-1.05%
Max Revenue beat(4)0.01%
Revenue beat(8)3
Avg Revenue beat(8)-0.43%
Revenue beat(12)5
Avg Revenue beat(12)-0.16%
Revenue beat(16)7
Avg Revenue beat(16)-0.07%
PT rev (1m)2.04%
PT rev (3m)5.63%
EPS NQ rev (1m)0%
EPS NQ rev (3m)5.75%
EPS NY rev (1m)-0.54%
EPS NY rev (3m)6.05%
Revenue NQ rev (1m)0.01%
Revenue NQ rev (3m)3.78%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.73%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 45.45 | ||
| Fwd PE | 37.59 | ||
| P/S | 13.25 | ||
| P/FCF | 77.19 | ||
| P/OCF | 37.91 | ||
| P/B | 10.91 | ||
| P/tB | 11.32 | ||
| EV/EBITDA | 37.56 |
EPS(TTM)1.78
EY2.2%
EPS(NY)2.15
Fwd EY2.66%
FCF(TTM)1.05
FCFY1.3%
OCF(TTM)2.13
OCFY2.64%
SpS6.1
BVpS7.41
TBVpS7.15
PEG (NY)3.31
PEG (5Y)3.27
Graham Number17.23
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 19.41% | ||
| ROE | 21.91% | ||
| ROCE | 24.39% | ||
| ROIC | 19.3% | ||
| ROICexc | 42.22% | ||
| ROICexgc | 45.68% | ||
| OM | 30.67% | ||
| PM (TTM) | 26.61% | ||
| GM | 76.96% | ||
| FCFM | 17.17% |
ROA(3y)17.74%
ROA(5y)13.28%
ROE(3y)21.21%
ROE(5y)15.76%
ROIC(3y)18.78%
ROIC(5y)N/A
ROICexc(3y)57.41%
ROICexc(5y)N/A
ROICexgc(3y)63.62%
ROICexgc(5y)N/A
ROCE(3y)23.73%
ROCE(5y)N/A
ROICexgc growth 3Y-6.9%
ROICexgc growth 5Y0.27%
ROICexc growth 3Y-6.89%
ROICexc growth 5Y-0.24%
OM growth 3Y8.49%
OM growth 5Y5.96%
PM growth 3Y5.58%
PM growth 5Y0.99%
GM growth 3Y0.12%
GM growth 5Y-0.04%
F-Score4
Asset Turnover0.73
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 1738.97% | ||
| Cap/Sales | 17.79% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 110.32% | ||
| Profit Quality | 64.54% | ||
| Current Ratio | 8.78 | ||
| Quick Ratio | 7.51 | ||
| Altman-Z | 51.33 |
F-Score4
WACC8.75%
ROIC/WACC2.21
Cap/Depr(3y)801.75%
Cap/Depr(5y)501.1%
Cap/Sales(3y)9.26%
Cap/Sales(5y)6.31%
Profit Quality(3y)60.91%
Profit Quality(5y)134.72%
High Growth Momentum
Growth
EPS 1Y (TTM)11.25%
EPS 3Y25.74%
EPS 5Y13.92%
EPS Q2Q%16.67%
EPS Next Y13.75%
EPS Next 2Y14.21%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)11.74%
Revenue growth 3Y20.55%
Revenue growth 5Y13.71%
Sales Q2Q%13.84%
Revenue Next Year10.65%
Revenue Next 2Y11.02%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y11.02%
EBIT growth 3Y30.78%
EBIT growth 5Y20.49%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y86.2%
FCF growth 3Y16.9%
FCF growth 5Y11.53%
OCF growth 1Y79.39%
OCF growth 3Y31.53%
OCF growth 5Y20.16%
IRADIMED CORP / IRMD FAQ
Can you provide the ChartMill fundamental rating for IRADIMED CORP?
ChartMill assigns a fundamental rating of 7 / 10 to IRMD.
What is the valuation status of IRADIMED CORP (IRMD) stock?
ChartMill assigns a valuation rating of 4 / 10 to IRADIMED CORP (IRMD). This can be considered as Fairly Valued.
Can you provide the profitability details for IRADIMED CORP?
IRADIMED CORP (IRMD) has a profitability rating of 9 / 10.
How financially healthy is IRADIMED CORP?
The financial health rating of IRADIMED CORP (IRMD) is 9 / 10.
Is the dividend of IRADIMED CORP sustainable?
The dividend rating of IRADIMED CORP (IRMD) is 3 / 10 and the dividend payout ratio is 39.33%.